SN//Connect

Practical Guidance on Mental Health and Physician Burnout

Latest News

CAR T-Cell Therapy is a ‘Revolution in Cancer Immunotherapy’

Chimeric antigen receptor (CAR) T-cell therapy is "paradigm changing" -- a "revolution in cancer immunotherapy." This treatment has ushered in a new era of therapy for blood cancer patients.

Learn More

CAR T-Cell Therapy Produces ‘Remarkable’ Results in Multiple Myeloma, but It’s Still Not a Cure

Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, as evidenced by a trio of investigational therapies presented at this year's ASCO conference. 

Learn More

CLL — Deciding Which BTK Inhibitor is Best in the Upfront Setting

Chronic lymphocytic leukemia (CLL) patients now have several frontline treatment options available to them, including two FDA-approved Bruton tyrosine kinase (BTK) inhibitors: ibrutinib (brand name: Imbruvica) and acalabrutinib (brand name: Calquence). How do you determine which of these medications is best for a particular patient?

Learn More

Concrete Steps for Addressing Racial Disparities in Your Practice

Both anecdotal evidence and multiple studies have documented disturbing disparities in cancer care, morbidity, and mortality among various populations. “We’ve known that cancer disparities have existed for decades,” Dr. Karen Winkfield, radiation oncologist at Vanderbilt University, tells SurvivorNet Connect. She explains that CDC graphs and charts as far back as the 1970s show Blacks dying from cancers at a much higher rate than other racial or ethnic groups. “Black men, for example, are dying of prostate cancer at about twice the rate of white men,” she says.

Learn More

Could Durvalumab (Imfinzi) Improve Survival in Early-Stage NSCLC?

The PACIFIC trial revealed a clear survival benefit to giving durvalumab to patients with stage III unresectable non-small cell lung cancer (NSCLC) following chemoradiation. With the PACIFIC-4 study, researchers want to learn whether patients might benefit from this checkpoint inhibitor in the earlier stages of the disease.

Learn More

Could Ibrutinib Combined With Other Targeted Therapies and Chemo Be ‘the Future’ of B-Cell Lymphoma Treatment?

New research is enhancing our understanding of ibrutinib -- a Bruton's tyrosine kinase (BTK) inhibitor used to treat several different types of lymphoma, including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma. It has also produced positive responses in B-cell lymphoma, but is so far only used in patients with relapsed/refractory disease.

Learn More

COVID-19 Could Lead to Dangerous Levels of Physician Burnout — How Can We Change the Culture of Medicine?

Working to the extreme is a hazard of the medical profession. In January 2020, 42% of physicians surveyed reported feeling exhausted and overwhelmed, otherwise known as burnout. And that was before COVID-19 sent a flood of new patients into medical offices and hospitals.

Learn More

COVID-19 Energized the HCP Community in the Early Days

Before the COVID-19 pandemic, levels of HCP burnout had reached epidemic proportions. "Health care has been suffering from burnout for many, many years. All of the regulatory challenges, all of the insurance and administrative challenges that face health care has really sapped the joy for many providers," Dr. Ted Teknos, a head and neck cancer surgeon at University Hospitals in Cleveland, tells SurvivorNet Connect. According to Dr. Teknos, there was a silver lining when the pandemic first began as many health care workers felt reenergized with a purpose.

Learn More